ATYR
aTyr Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.50
−1.59%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
Market Cap
$48.60M
MomentumView details →
1D Return
−1.59%
YTD Return
−36.16%
RSI (14)
45.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
Market Cap
$48.60M
RSI (14)
45.8
MomentumView details →
1D Return
−1.59%
YTD Return
−36.16%
SummaryUpdated Jun 1, 2026
aTyr Pharma, Inc. (NASDAQ:ATYR) is a clinical-stage biotherapeutics company founded in 2005 and headquartered in San Diego, California. The company specializes in discovering and developing novel medicines based on immunological pathways, with a particular focus on treating rare inflammatory and fibrotic diseases. aTyr has evolved from its early research into aminoacyl-tRNA synthetases to become a focused developer of potential treatments for serious lung diseases, with its lead candidate efzofitimod currently in late-stage clinical trials for pulmonary sarcoidosis.
Similar companies
Latest newsMore news →
aTyr Pharma provided an update on the expected timing of an FDA response to its protocol submitted in June 2026 for a planned Phase 3 study of efzofitimod in pulmonary sarcoidosis.3d agoaTyr Pharma announced a corporate restructuring, including a workforce reduction of approximately 60%, to support its efzofitimod program in ILD.28d ago